Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study (Q44399798)

2 December 2017

Evidence for a GVL effect following reduced-intensity allo-SCT in ALL: a British Society of Blood and Marrow Transplantation study (English)

1 reference

2 December 2017

11

A K Fielding

1 reference

2 December 2017

P G Medd

1

1 reference

2 December 2017

A J Peniket

2

1 reference

2 December 2017

T J Littlewood

3

1 reference

2 December 2017

R Pearce

4

1 reference

2 December 2017

J Perry

5

1 reference

2 December 2017

K E Kirkland

6

1 reference

2 December 2017

B E Shaw

7

1 reference

2 December 2017

M N Potter

8

1 reference

2 December 2017

C F Craddock

9

1 reference

2 December 2017

D W Milligan

10

1 reference

2 December 2017

D I Marks

12

1 reference

2 December 2017

G Cook

13

1 reference

2 December 2017

British Society of Blood and Marrow Transplantation

14

1 reference

2 December 2017

language of work or name

English

0 references

publication date

14 January 2013

1 reference

Bone Marrow Transplantation

2 December 2017

1 reference

2 December 2017

48

1 reference

2 December 2017

7

1 reference

2 December 2017

982-987

1 reference

https://scigraph.springernature.com/pub.10.1038/bmt.2012.261

2 December 2017

0 references

cites work

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Reduced-intensity stem-cell transplantation for adult acute lymphoblastic leukemia: a retrospective study of 33 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Defining the intensity of conditioning regimens: working definitions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Graft-versus-disease effect following allogeneic transplantation for acute leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

A Novel GVHD-Prophylaxis with Low-Dose Alemtuzumab in Allogeneic Sibling or Unrelated Donor Hematopoetic Cell Transplantation: The Feasibility of Deescalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Chemoimmunotherapy in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

7 January 2021

Reduced-intensity versus conventional myeloablative conditioning allogeneic stem cell transplantation for patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

7 January 2021

Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

7 January 2021

Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2012.261

7 January 2021

Identifiers

DOI

10.1038/BMT.2012.261

1 reference

2 December 2017

1 reference